Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Οι συνταγές μου Αποθηκεύστε τις συνταγές σας και μοιραστείτε τις εύκολα και με ασφάλεια
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Ενδείξεις και αγωγές Βρείτε θεραπευτικές ενδείξεις και αγωγές για νόσους, συμπτώματα και ιατρικές πράξεις
Γνωρίζατε ότι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

SUDAFED NOSE SPRAY Aqueous solution (2019)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Non-Drowsy Sudafed Decongestant Nasal Spray. Sudafed Blocked Nose Spray. Sudafed Mucus Relief 0.1% Nasal Spray. Sudafed Sinus-Ease 0.1% Nasal Spray.

Qualitative and quantitative composition

This product is an aqueous solution of Xylometazoline Hydrochloride 0.1% w/v presented in a metered-dose pack, delivering 0.14 ml per actuation. For the full list of excipients, see section 6.1.

Pharmaceutical form

Aqueous solution.

Therapeutic indications

This product is indicated for the symptomatic relief of nasal congestion associated with the common cold, influenza, sinusitis, allergic and non-allergic rhinitis, and other upper respiratory tract allergies. ...

Posology and method of administration

Posology Adults and children 12 years and over One spray to be expressed into each nostril 2-3 times daily, as necessary. Maximum daily dose: 3 sprays in 24 hours. Use for more than seven consecutive days ...

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Children under 12 years of age. This product is contraindicated in individuals who are taking or have taken monoamine ...

Special warnings and precautions for use

There is minimal systemic absorption with topically applied imidazoline sympathomimetics such as xylometazoline, however, this product should be used with caution in patients suffering coronary artery ...

Interaction with other medicinal products and other forms of interaction

Due to the low systemic absorption of xylometazoline when administered intra-nasally, interaction with drugs administered via other routes is considered unlikely. No interaction studies have been performed. ...

Pregnancy and lactation

Pregnancy There are no adequate and well-controlled studies in pregnant women. This product should not be used during pregnancy unless the potential benefit of treatment to the mother outweighs the possible ...

Effects on ability to drive and use machines

It is not known if xylometazoline has an effect on the ability to drive and use machines.

Undesirable effects

Adverse Drug Reactions (ADRs) identified during clinical trials and post-marketing experience with xylometazoline are listed below by System Organ Class (SOC). The frequencies are defined in accordance ...

Overdose

Symptoms Systemic action is unlikely when applied nasally due to the local vasoconstriction that inhibits absorption. If systemic absorption does occur xylometazoline as an α<sub>2</sub>-adrenergic agonist ...

Pharmacodynamic properties

Pharmacotherapeutic group: Nasal preparations, sympathomimetics, plain ATC code: R01AA07 It acts directly on α-adrenoreceptors but does not act on β-receptors. When used topically as a nasal decongestant, ...

Pharmacokinetic properties

Absorption, Distribution, Biotransformation and Elimination Little information is available concerning the absorption, distribution, Biotransformation and elimination of xylometazoline in man. Absorption ...

Preclinical safety data

Mutagenicity There is insufficient information available to determine whether xylometazoline has mutagenic potential. Carcinogenicity There is insufficient information available to determine whether xylometazoline ...

List of excipients

Benzalkonium chloride solution Disodium edetate Sodium dihydrogen phosphate dihydrate Sodium monohydrogen phosphate dihydrate Sodium chloride Sorbitol solution, 70% (Non crystalline) Purified water

Incompatibilities

Not applicable.

Shelf life

3 years.

Special precautions for storage

Do not store above 25°C.

Nature and contents of container

Amber glass bottle of either 10 ml or 15 ml nominal fill volume. The bottle is sealed with an integral snap-on metered 0.14 ml pump consisting of a white plastic actuator and natural polyethylene pull-off ...

Special precautions for disposal and other handling

No special requirements. Any unused product or waste material should be disposed of in accordance with local requirements.

Marketing authorization holder

McNeil Products Limited, Foundation Park, Roxborough Way, Maidenhead, Berkshire SL6 3UG, United Kingdom

Marketing authorization number(s)

PL 15513/0074

Date of first authorization / renewal of the authorization

21/April/1999

Date of revision of the text

03 January 2019

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:

Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.